# EDGAR Filing Document

**Accession Number:** 0001540159
**File Stem:** 0001104659-23-037136
**Filing Date:** 2023-3
**Character Count:** 44540
**Document Hash:** 2374faa4170462289c3d149a85790c62
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-037136.hdr.sgml**: 20230327

**ACCESSION NUMBER**: 0001104659-23-037136

**CONFORMED SUBMISSION TYPE**: 10-K/A

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20220930

**FILED AS OF DATE**: 20230327

**DATE AS OF CHANGE**: 20230327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Edesa Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001540159
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37619
- **FILM NUMBER:** 23764820

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SPY COURT
- **CITY:** MARKHAM
- **STATE:** A6
- **ZIP:** L3R 5H6
- **BUSINESS PHONE:** (905) 475-1234

**MAIL ADDRESS:**
- **STREET 1:** 100 SPY COURT
- **CITY:** MARKHAM
- **STATE:** A6
- **ZIP:** L3R 5H6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stellar Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20120120

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K/A**

**(Amendment No. 1)**

(Mark One)

**⌧** **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the fiscal year ended September 30, 2022**

**OR**

---

| | |
|:---|:---|
| ◻ | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**For the transition period from to**

**Commission file number: 001-37619**

---

| |
|:---|
| **EDESA BIOTECH, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **British Columbia, Canada** | **N/A** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **100 Spy Court, Markham, ON, Canada L3R 5H6** | **(289) 800-9600** |
| (Address of principal executive offices and zip code) | (Registrant's telephone number, including area code) |

---

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Shares, without par value | EDSA | The Nasdaq Stock Market LLC |

---

**Securities registered pursuant to Section 12(g) of the Act: None**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ◻ No ⌧

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ◻ No ⌧

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ◻

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statement. ◻

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ◻ No ⌧

As of March 31, 2022, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the registrant's outstanding common shares held by nonaffiliates was approximately $35,987,404, which was calculated based on 15,462,287 common shares outstanding as of that date, of which 12,116,971 common shares were held by nonaffiliates at the closing price of the registrant's common shares on The Nasdaq Capital Market on such date.

As of December 14, 2022, the registrant had 19,353,351 common shares issued and outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE: NONE**

**EXPLANATORY NOTE**

This Amendment No. 1 to the Annual Report on Form 10-K of Edesa Biotech, Inc. for the year ended September 30, 2022 as filed with the Securities and Exchange Commission on December 16, 2022 (the "Original Form 10-K") is being filed only for the purpose of filing Exhibit 4.11, which was inadvertently omitted from the Original Form 10-K.

Except as otherwise expressly noted herein, this Amendment No. 1 does not modify or update in any way the Original Form 10-K, nor does it reflect events occurring after the filing of the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K.

**PART IV**

**Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The following documents are filed as a part of this Annual Report:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Financial Statements

The list of consolidated financial statements and notes required by this Item 15 (a) (1) is set forth in the "Index to Financial Statements" on page F-1 of this Annual Report.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Financial Statement Schedules

All schedules have been omitted because the required information is included in the financial statements or notes thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Exhibits

The exhibits listed on the Exhibit Index below are filed as part of this Annual Report.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [2.1\*](http://www.sec.gov/Archives/edgar/data/1540159/000114420419012862/tv515762_ex2-1.htm) | [Share Exchange Agreement, dated as of March 7, 2019, by and between Stellar Biotechnologies Inc., Edesa Biotech Inc. and the Edesa Shareholders (included as Exhibit 2.1 to the Company's Current Report on Form 8-K filed on March 8, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000114420419012862/tv515762_ex2-1.htm) |
| [3.1](http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofincorporation.htm) | [Certificate of Incorporation of the Company, dated June 12, 2007 (included as Exhibit 1(a) to the Company's Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofincorporation.htm) |
| [3.2](http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofamendment2008.htm) | [Certificate of Amendment of the Company, dated April 15, 2008 (included as Exhibit 1(b) to the Company's Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofamendment2008.htm) |
| [3.3](http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofcontinuation.htm) | [Certificate of Continuation of the Company, dated November 25, 2009 (included as Exhibit 1(c) to the Company's Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofcontinuation.htm) |
| [3.4](http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofchangename.htm) | [Certificate of Change of Name of the Company, dated April 7, 2010 (included as Exhibit 1(f) to the Company's Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofchangename.htm) |
| [3.5](http://www.sec.gov/Archives/edgar/data/1540159/000165495419013878/edsa_ex36.htm) | [Certificate of Change of Name of the Company, dated June 7, 2019 (included as Exhibit 3.6 to the Company's Annual Report on Form 10-K filed on December 12, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495419013878/edsa_ex36.htm) |
| [3.6](http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex31.htm) | [Amended and Restated Articles of Edesa Biotech, Inc. (included as Exhibit 3.1 to the Company's Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex31.htm) |
| [3.7](http://www.sec.gov/Archives/edgar/data/1540159/000165495420005548/edsa_ex32.htm) | [Notice of Articles of Edesa Biotech, Inc. (included as Exhibit 3.7 to the Company's Registration Statement on Form S-1 filed on April 11, 2022, and incorporated herein by reference)](http://www.sec.gov/Archives/edgar/data/1540159/000165495420005548/edsa_ex32.htm) |
| [4.1](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010204/edsa_ex41.htm) | [Specimen of common share certificate (included as Exhibit 4.1 to the Company's Registration Statement on Form S-3 filed on August 30, 2019 and incorporated herein by reference)](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010204/edsa_ex41.htm) |
| [4.2](http://www.sec.gov/Archives/edgar/data/1540159/000165495420000145/edsa_ex41.htm) | [Form of Class A Purchase Warrant issued to investors (included as Exhibit 4.1 to the Company's Current Report on Form 8-K filed on January 6, 2020 and incorporated herein by reference)](http://www.sec.gov/Archives/edgar/data/1540159/000165495420000145/edsa_ex41.htm) |
| [4.3](http://www.sec.gov/Archives/edgar/data/1540159/000165495420000145/edsa_ex4-3.htm) | [Form of Warrant issued to Brookline Capital Markets, a division of Arcadia Securities, LLC (included as Exhibit 4.3 to the Company's Current Report on Form 8-K filed on January 6, 2020 and incorporated herein by reference)](http://www.sec.gov/Archives/edgar/data/1540159/000165495420000145/edsa_ex4-3.htm) |
| [4.4](http://www.sec.gov/Archives/edgar/data/1540159/000114420418025796/tv492944_ex4-2.htm) | [Form of Warrant (included as Exhibit 4.2 to the Company's Registration Statement on Form S-1 filed on May 8, 2018, and incorporated herein by reference)](http://www.sec.gov/Archives/edgar/data/1540159/000114420418025796/tv492944_ex4-2.htm) |
| [4.5](http://www.sec.gov/Archives/edgar/data/1540159/000110465921029184/tm218114d1_ex4-1.htm) | [Form of Underwriter Warrant (included as Exhibit 4.1 to the Company's Current Report on Form 8-K/A filed on February 26, 2021 and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000110465921029184/tm218114d1_ex4-1.htm) |
| [4.6](http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-1.htm) | [Form of Pre-Funded Warrant (included as Exhibit 4.1 to the Company's Current Report on Form 8-K filed on March 23, 2022 and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-1.htm) |

---

---

| | |
|:---|:---|
| [4.7](http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-2.htm) | [Form of Private Placement Warrant (included as Exhibit 4.2 to the Company's Current Report on Form 8-K filed on March 23, 2022 and incorporated herein by reference)](http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-2.htm) |
| [4.8](http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-3.htm) | [Form of Placement Agent Warrant (included as Exhibit 4.3 to the Company's Current Report on Form 8-K filed on March 23, 2022 and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-3.htm) |
| [4.9](http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex4-1.htm) | [Form of Class A Warrant (included as Exhibit 4.1 to the Company's Current Report on Form 8-K filed on November 3, 2022 and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex4-1.htm) |
| [4.10](http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex4-2.htm) | [Form of Class B Warrant (included as Exhibit 4.2 to the Company's Current Report on Form 8-K filed on November 3, 2022 and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex4-2.htm) |
| [4.11](tm2310400d1_ex4-11.htm) | [Description of Securities (filed herewith).](tm2310400d1_ex4-11.htm) |
| [10.1](http://www.sec.gov/Archives/edgar/data/1540159/000114420414068912/v392175_ex10-14.htm) | [Advance Notice Policy, adopted October 31, 2013 (included as Exhibit 10.14 to the Company's Annual Report on Form 10-K filed on November 14, 2014, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000114420414068912/v392175_ex10-14.htm) |
| [10.2@](http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-2.htm) | [Employment Agreement by and between the Company and Pardeep Nijhawan, dated June 14, 2019 (included as Exhibit 10.2 to the Company's Current Report on Form 8-K/A filed on June 20, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-2.htm) |
| [10.3@](http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-3.htm) | [Employment Agreement by and between the Company and Michael Brooks, dated June 14, 2019 (included as Exhibit 10.3 to the Company's Current Report on Form 8-K/A filed on June 20, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-3.htm) |
| [10.4@](http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-4.htm) | [Form of Indemnification Agreement, by and between the Company and each of its directors and executive officers (included as Exhibit 10.4 to the Company's Current Report on Form 8-K/A filed on June 20, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-4.htm) |
| [10.5@](http://www.sec.gov/Archives/edgar/data/1540159/000165495419012009/edsa_ex101.htm) | [2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 25, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495419012009/edsa_ex101.htm) |
| [10.6@](http://www.sec.gov/Archives/edgar/data/1540159/000165495421004573/edsa_ex101.htm) | [Amendment No. 1 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on April 23, 2021, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495421004573/edsa_ex101.htm) |
| [10.7](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex101.htm) | [Lease, dated as of January 1, 2017, by and between the Registrant and 1968160 Ontario Inc. (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex101.htm) |
| [10.8+](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex102.htm) | [Exclusive License Agreement, dated as of June 29, 2016, by and between the Registrant and Yissum Research Development Company (included as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex102.htm) |
| [10.9](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex103.htm) | [First Amendment to Exclusive License Agreement, dated April 3, 2017, by and between the Registrant and Yissum Research Development Company (included as Exhibit 10.3 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex103.htm) |
| [10.10](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex104.htm) | [Second Amendment to Exclusive License Agreement, dated May 7, 2017, by and between the Registrant and Yissum Research Development Company (included as Exhibit 10.4 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex104.htm) |

---

---

| | |
|:---|:---|
| [10.11+#](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex1011.htm) | [Third Amendment to Exclusive License Agreement, dated October 26, 2022, by and between the Registrant and Yissum Research Development Company.](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex1011.htm) |
| [10.12+](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex106.htm) | [License and Development Agreement, dated as of August 27, 2017, by and between the Registrant and Pendopharm, a division of Pharmascience Inc. (included as Exhibit 10.6 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex106.htm) |
| [10.13+](http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex101.htm) | [License Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex101.htm) |
| [10.14+](http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex102.htm) | [Purchase Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (included as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex102.htm) |
| [10.15@](http://www.sec.gov/Archives/edgar/data/1540159/000165495420013236/edsa_ex1021.htm) | [Employment Agreement by and between the Company and Kathi Niffenegger, dated December 1, 2020 (included as Exhibit 10.21 to the Company's Annual Report on Form 10-K filed on December 7, 2020, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495420013236/edsa_ex1021.htm) |
| [10.16+](http://www.sec.gov/Archives/edgar/data/1540159/000165495421001111/edsa_ex101.htm) | [Strategic Innovation Fund Agreement among Edesa Biotech Research, Inc., Edesa Biotech, Inc., and her Majesty the Queen in right of Canada as represented by the Minister of Industry, dated February 2, 2021 (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 3, 2021, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495421001111/edsa_ex101.htm) |
| [10.17+](http://www.sec.gov/Archives/edgar/data/1540159/000165495421003044/edsa_ex101.htm) | [Exclusive License Agreement, dated as of March 16, 2021, by and between the Edesa Biotech Research, Inc. and Dr. Saul Yedgar (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on March 22, 2021, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495421003044/edsa_ex101.htm) |
| [10.18@](http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex103.htm) | [Amendment to Employment Agreement, entered into on March 19, 2021, by and between Par Nijhawan and Edesa Biotech, Inc. (included as Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex103.htm) |
| [10.19@](http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex104.htm) | [Amendment to Employment Agreement, entered into on March 19, 2021, by and between Kathi Niffenegger and Edesa Biotech USA, Inc. (included as Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex104.htm) |
| [10.20@](http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex105.htm) | [Amendment to Employment Agreement, entered into on March 19, 2021, by and between Michael Brooks and Edesa Biotech, Inc. (included as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex105.htm) |
| [10.21](http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex10-1.htm) | [Form of Securities Purchase Agreement, dated March 21, 2022, by and between the Company and the Purchaser (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on March 23, 2022 and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex10-1.htm) |
| [10.22@](http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex101.htm) | [Amendment to Employment Agreement, entered into on April 12, 2022, by and between Par Nijhawan and Edesa Biotech, Inc. (included as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex101.htm) |

---

---

| | |
|:---|:---|
| [10.23@](http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex102.htm) | [Amendment to Employment Agreement, entered into on April 12, 2022, by and between Kathi Niffenegger and Edesa Biotech USA, Inc. (included as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex102.htm) |
| [10.24@](http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex103.htm) | [Amendment to Employment Agreement, entered into on April 12, 2022, by and between Michael Brooks and Edesa Biotech USA, Inc. (included as Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex103.htm) |
| [10.25](http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex10-1.htm) | [Form of Non-U.S. Subscription Agreement (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on November 3, 2022 and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex10-1.htm) |
| [10.26](http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex10-2.htm) | [Form of U.S. Subscription Agreement (included as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on November 3, 2022 and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex10-2.htm) |
| [14.1](http://www.sec.gov/Archives/edgar/data/1540159/000165495419013878/edsa_ex141.htm) | [Code of Ethics and Business Conduct (included as Exhibit 14.1 to the Company's Annual Report on Form 10-K filed on December 12, 2019, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495419013878/edsa_ex141.htm) |
| [21](http://www.sec.gov/Archives/edgar/data/1540159/000165495420013236/edsa_ex21.htm) | [Subsidiaries of Edesa Biotech, Inc. (included as Exhibit 21 to the Company's Annual Report on Form 10-K filed on December 7, 2020, and incorporated herein by reference).](http://www.sec.gov/Archives/edgar/data/1540159/000165495420013236/edsa_ex21.htm) |
| [23.1#](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex231.htm) | [Consent of MNP LLP.](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex231.htm) |
| [24.1#](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_10k.htm#pow) | [Power of Attorney (included on signature page).](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_10k.htm#pow) |
| [31.1](tm2310400d1_ex31-1.htm) | [Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).](tm2310400d1_ex31-1.htm) |
| [31.2](tm2310400d1_ex31-2.htm) | [Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).](tm2310400d1_ex31-2.htm) |
| [32.1\*\*](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex321.htm) | [Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex321.htm) |
| [32.2\*\*](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex322.htm) | [Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex322.htm) |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Presentation Linkbase Document |

---

\* All schedules and exhibits to the Share Exchange Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.

\*\* The information in this exhibit (included as an exhibit to the Company's Annual Report on Form 10-K filed with the Commission on December 16, 2022) is furnished and deemed not filed with the Securities and Exchange Commission for purposes of section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of Edesa Biotech, Inc. under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

@ Management contract or compensatory plan or arrangement.

+ Portions of this exhibit have been omitted pursuant to Rule 601(b)(10)(iv) of Regulation S-K.

# Previously filed.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **EDESA BIOTECH, INC.** |
| Date: March 27, 2023 | */s/ Pardeep Nijhawan* |
|  | **Pardeep Nijhawan, MD** |
|  | *Director, Chief Executive Officer and Corporate Secretary (Principal Executive Officer)* |

---

## Exhibit 4.11

**Exhibit 4.11**

**DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT** 

**TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934**

The following description of our capital shares summarizes the material terms and provisions of our capital shares based on the provisions of our Amended and Restated Articles (the "Articles"). The following description of our capital shares does not purport to be complete and is subject to, and qualified in its entirety by, (i) our Articles which is an exhibit to the Annual Report on Form 10-K filed with the Securities and Exchange Commission, of which this Exhibit 4.11 forms a part and (ii) the British Columbia *Business Corporations Act*.

**General** 

We are authorized to issue an unlimited number of common shares and preferred shares, no par value. As of March 27, 2023, there were 20,058,665 common shares outstanding and no preferred shares outstanding.

**Common Shares**

The holders of our common shares are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders. Our shareholders do not have cumulative voting rights in the election of directors. Subject to preferences that may be applicable to any outstanding preferred shares, the holders of common shares are entitled to receive ratably only those dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common shares are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding preferred shares. Holders of common shares have no preemptive or other subscription or conversion rights. There are no redemption or sinking fund provisions applicable to our common shares. Common shares outstanding, and to be issued, are, and will be, fully paid and non-assessable. Additional shares of authorized common shares may be issued, as authorized by our board of directors from time to time, without shareholder approval, except as may be required by The Nasdaq Capital Market.

**Preferred Shares**

Pursuant to our Articles, and the provisions of the British Columbia *Business Corporations Act*, our board of directors has the authority, without further action by the shareholders (unless such shareholder action is required by applicable law or the rules of The Nasdaq Capital Market), to designate and issue an unlimited number of preferred shares in one of more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences and rights of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. Preferred shares, if issued, will be fully paid and non-assessable.

The board of directors' authority to determine the terms of any such preferred shares include, without limitation: (i) the designation of each series and the number of preferred shares that will constitute each such series; (ii) the dividend rate or amount, if any, for each series; (iii) the price at which, and the terms and conditions on which, the preferred shares of each series may be redeemed, if such shares are redeemable; (iv) the terms and conditions, if any, upon which preferred shares of such series may be converted into shares of other classes or series of shares of the Company, or other securities; and (v) the maturity date, if any, for each such series; but no such special rights or restriction shall contravene any other provision of Part 26 of the Articles of the Company.

The issuance of preferred shares may or may not have a dilutive effect on the voting rights of shareholders owning common shares, depending on the rights and preferences set by the board of directors. Preferred shares may be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. However, except for such rights relating to the election of directors on a default in payment of dividends as may be attached to any series of the preferred shares by the board of directors or in connection with convertible preferred shares, the holders of preferred shares shall not be entitled, as such, to receive notice of, or to attend or vote at, any general meeting of shareholders of the Company. Section 61 of the British Columbia *Business Corporations Act* provides that the special rights attached to preferred shares may not be prejudiced or interfered with unless the shareholders holding such class of shares consent to such matter by a special resolution of such holders of preferred shares. Additionally, the issuance of preferred shares may have the effect of decreasing the market price of our common shares.

**Anti-takeover Provisions of our Articles of Incorporation**

In addition to the board of directors' ability to issue preferred shares, our Articles, as amended, contain other provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and which may have the effect of delaying, deferring or preventing a future takeover or change in control of our Company unless such takeover or change in control is approved by our board of directors. These provisions include advance notice procedures for shareholder proposals and a supermajority vote requirement for business combinations.

**Advance Notice Procedures for Shareholder Proposals**

Effective October 31, 2013, our board of directors adopted an advance notice policy (the "Advance Notice Policy") with immediate effect for the purpose of providing our shareholders, directors and management with a clear framework for nominating our directors in connection with any annual or special meeting of shareholders. The Advance Notice Policy was approved by the shareholders at our annual meeting on February 13, 2014.

*Purpose of the Advance Notice Policy*. Our directors are committed to: (i) facilitating an orderly and efficient annual general or, where the need arises, special meeting, process; (ii) ensuring that all shareholders receive adequate notice of the director nominations and sufficient information with respect to all nominees; and (iii) allowing shareholders to register an informed vote having been afforded reasonable time for appropriate deliberation. The purpose of the Advance Notice Policy is to provide our shareholders, directors and management with a clear framework for nominating directors. The Advance Notice Policy fixes a deadline by which holders of record of our common shares must submit director nominations to the Company prior to any annual or special meeting of shareholders and sets forth the information that a shareholder must include in the notice to the Company for the notice to be in proper written form in order for any director nominee to be eligible for election at any annual or special meeting of shareholders.

*Terms of the Advance Notice Policy*. The Advance Notice Policy provides that advance notice to the Company must be made in circumstances where nominations of persons for election to our board of directors are made by shareholders of the Company other than pursuant to: (i) a "proposal" made in accordance with Division 7 of Part 5 of the British Columbia *Business Corporations Act*; or (ii) a requisition of the shareholders made in accordance with section 167 of the British Columbia *Business Corporations Act*. Among other things, the Advance Notice Policy fixes a deadline by which holders of record of our common shares must submit director nominations to the secretary of the Company prior to any annual or special meeting of shareholders and sets forth the specific information that a shareholder must include in the written notice to the secretary of the Company for an effective nomination to occur. No person will be eligible for election as a director of the Company unless nominated in accordance with the provisions of the Advance Notice Policy.

In the case of an annual meeting of shareholders, notice to the Company must be made not less than 30 nor more than 65 days prior to the date of the annual meeting; provided, however, that in the event that the annual meeting is to be held on a date that is less than 50 days after the date on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close of business on the 10th day following such public announcement.

In the case of a special meeting of shareholders (which is not also an annual meeting), notice to the Company must be made not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting was made.

Our board of directors may, in its sole discretion, waive any requirement of the Advance Notice Policy.

**Provisions of British Columbia Law Governing Business Combinations**

All provinces of Canada have adopted National Instrument 62-104 entitled "*Take-Over Bids and Issuer Bids*" and related forms to harmonize and consolidate take-over bid and issuer bid regimes nationally ("NI 62-104"). The Canadian Securities Administrators, or CSA, have also issued National Policy 62-203 entitled "*Take-Over Bids and Issuer Bids*" (the "National Policy") which contains regulatory guidance on the interpretation and application of NI 62-104 and on the conduct of parties involved in a bid. The National Policy and NI 62-104 are collectively referred to as the "Bid Regime." The National Policy does not have the force of law, but is an indication by the CSA of what the intentions and desires of the regulators are in the areas covered by their policies. Unlike some regimes where the take-over bid rules are primarily policy-driven, in Canada the regulatory framework for take-over bids is primarily rules-based, which rules are supported by policy.

A "take-over bid" or "bid" is an offer to acquire outstanding voting or equity securities of a class made to any person who is in one of the provinces of Canada or to any securityholder of an offeree issuer whose last address as shown on the books of a target is in such province, where the securities subject to the offer to acquire, together with the securities "beneficially owned" by the offeror, constitute in the aggregate 20% or more of the outstanding securities of that class of securities at the date of the offer to acquire. For the purposes of the Bid Regime, a security is deemed to be "beneficially owned" by an offeror as of a specific date if the offeror is the beneficial owner of a security convertible into the security within 60 days following that date, or has a right or obligation permitting or requiring the offeror, whether or not on conditions, to acquire beneficial ownership of the security within 60 days by a single transaction or a series of linked transactions. Offerors are also subject to early warning requirements, where an offeror who acquires "beneficial ownership of", or control or direction over, voting or equity securities of any class of a reporting issuer or securities convertible into, voting or equity securities of any class of a target that, together with the offeror's securities, would constitute 10% or more of the outstanding securities of that class must promptly publicly issue and file a news release containing certain prescribed information, and, within two business days, file an early warning report containing substantially the same information as is contained in the news release.

In addition, where an offeror is required to file an early warning report or a further report as described and the offeror acquires or disposes of beneficial ownership of, or the power to exercise control or direction over, an additional 2% or more of the outstanding securities of the class, or disposes of beneficial ownership of outstanding securities of the class below 10%, the offeror must issue an additional press release and file a new early warning report. Any material change in a previously filed early warning report also triggers the issuance and filing of a new press release and early warning report. During the period commencing on the occurrence of an event in respect of which an early warning report is required and terminating on the expiry of one business day from the date that the early warning report is filed, the offeror may not acquire or offer to acquire beneficial ownership of any securities of the class in respect of which the early warning report was required to be filed or any securities convertible into securities of that class. This requirement does not apply to an offeror that has beneficial ownership of, or control or direction over, securities that comprise 20% or more of the outstanding securities of the class.

Related party transactions, issuer bids and insider bids are subject to additional regulation that may differ depending on the particular jurisdiction of Canada in which it occurs.

**Transfer Agent and Registrar**

The transfer agent and registrar for our common shares is Computershare Investor Services Inc. located at 100 University Avenue, 8th Floor, Toronto, Ontario M5J 2Y1, and its telephone number is 1-800-564-6253.

**Listing on The Nasdaq Capital Market**

Our common shares are listed on The Nasdaq Capital Market under the symbol "EDSA."

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Pardeep Nijhawan, certify that:

1. I have reviewed this Annual Report on Form 10-K/A of Edesa Biotech, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

---

| | | |
|:---|:---|:---|
| Date: March 27, 2023 | By: | /s/ Pardeep Nijhawan |
|  |  | Pardeep Nijhawan<br> Director, Chief Executive Officer and Corporate Secretary<br> (Principal Executive Officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Kathi Niffenegger, certify that:

1. I have reviewed this Annual Report on Form 10-K/A of Edesa Biotech, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

---

| | | |
|:---|:---|:---|
| Date: March 27, 2023 | By: | /s/ Kathi Niffenegger |
|  |  | Kathi Niffenegger<br> Chief Financial Officer<br> (Principal Financial Officer) |

---